TPX-100 200mg, Once weekly for 4 weeks for osteoarthritis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Mar 2025: Trial registered, NCT06865079
  2. 9 May 2025: Trial started, NCT06865079

The trials

NCT06865079: 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

State
Under way
Phase
Phase 2
People
270 planned
Started
9 May 2025
Primary completion
25 Mar 2027
Arms
TPX-100 (200 mg per dose)
Results
None posted
  1. 7 Mar 2025: Trial registered
  2. 9 May 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.